Characteristics at baseline and study end: metformin and OCP group
| Characteristic . | Metformin . | . | OCP . | . | P value for change over study: metformin vs. OCP . | ||
|---|---|---|---|---|---|---|---|
| . | Before . | After . | Before . | After . | . | ||
| n | 19 | 19 | |||||
| BMI (kg/m2) | 38.4 ± 1.6 | 37.7 ± 1.6 | 35.3 ± 1.8 | 35.3 ± 1.8 | 0.26 | ||
| Weight (kg) | 105.2 ± 4.7 | 103.4 ± 4.6 | 94.1 ± 5.0 | 94.2 ± 5.0 | 0.24 | ||
| Waist circumference (cm) | 112.6 ± 3.5 | 113.7 ± 4.0 | 105.1 ± 3.8 | 107.2 ± 3.5 | 0.52 | ||
| Waist-to-hip ratio | 0.9 ± 0 | 0.9 ± 0 | 0.9 ± 0 | 0.9 ± 0 | 0.65 | ||
| hsCRP (mg/l) | 4.2 ± 0.68 | 3.8 ± 0.73 | 4.6 ± 0.93 | 7.4 ± 2.0 | 0.03 | ||
| Testosterone (nmol/l) | 2.4 ± 0.1 | 2.2 ± 0.3 | 2.1 ± 0.2 | 1.7 ± 0.1 | 0.87 | ||
| SHBG (nmol/l) | 32.4 ± 4.4 | 43.2 ± 9.6 | 31.7 ± 2.8 | 133.7 ± 17*† | <0.01 | ||
| FAI | 9.9 ± 1.5 | 10.7 ± 2.7 | 8.5 ± 1.7 | 1.8 ± 0.3*† | <0.01 | ||
| Cholesterol (mmol/l) | 5.3 ± 0.3 | 5.1 ± 0.3 | 5.1 ± 0.2 | 4.9 ± 0.2 | 0.81 | ||
| HDL cholesterol (mmol/l) | 1.2 ± 0.1 | 1.1 ± 0.1* | 1.4 ± 0.1 | 1.4 ± 0.1† | 0.01 | ||
| LDL cholesterol (mmol/l) | 3.4 ± 0.3 | 3.2 ± 0.3 | 3.2 ± 0.2 | 2.7 ± 0.2* | 0.15 | ||
| Triglycerides (mmol/l) | 1.6 ± 0.1 | 1.6 ± 0.2 | 1.2 ± 0.1 | 1.7 ± 0.2* | <0.01 | ||
| Fasting glucose (mmol/l) | 4.7 ± 0.2 | 4.6 ± 0.2 | 4.4 ± 0.1 | 4.3 ± 0.1 | 0.74 | ||
| Fasting insulin (mU/l) | 21.5 ± 4.2 | 17.8 ± 5 | 21 ± 4.4 | 20.8 ± 2.9 | 0.1 | ||
| AUC insulin (mU · l−1 · 120 min−1) | 12,333.9 ± 2,046.4 | 8,054.7 ± 1,090.6* | 9,339.8 ± 1,531.5 | 12,413.5 ± 1,616.7*† | <0.01 | ||
| HOMA | 4.7 ± 1.1 | 4.2 ± 1.7 | 4.2 ± 0.9 | 4 ± 0.6 | 0.1 | ||
| RBP4 (μg/l) | 35.9 ± 7.4 | 43.7 ± 6.3 | 35.7 ± 5.3 | 42.6 ± 5.5 | 0.92 | ||
| Characteristic . | Metformin . | . | OCP . | . | P value for change over study: metformin vs. OCP . | ||
|---|---|---|---|---|---|---|---|
| . | Before . | After . | Before . | After . | . | ||
| n | 19 | 19 | |||||
| BMI (kg/m2) | 38.4 ± 1.6 | 37.7 ± 1.6 | 35.3 ± 1.8 | 35.3 ± 1.8 | 0.26 | ||
| Weight (kg) | 105.2 ± 4.7 | 103.4 ± 4.6 | 94.1 ± 5.0 | 94.2 ± 5.0 | 0.24 | ||
| Waist circumference (cm) | 112.6 ± 3.5 | 113.7 ± 4.0 | 105.1 ± 3.8 | 107.2 ± 3.5 | 0.52 | ||
| Waist-to-hip ratio | 0.9 ± 0 | 0.9 ± 0 | 0.9 ± 0 | 0.9 ± 0 | 0.65 | ||
| hsCRP (mg/l) | 4.2 ± 0.68 | 3.8 ± 0.73 | 4.6 ± 0.93 | 7.4 ± 2.0 | 0.03 | ||
| Testosterone (nmol/l) | 2.4 ± 0.1 | 2.2 ± 0.3 | 2.1 ± 0.2 | 1.7 ± 0.1 | 0.87 | ||
| SHBG (nmol/l) | 32.4 ± 4.4 | 43.2 ± 9.6 | 31.7 ± 2.8 | 133.7 ± 17*† | <0.01 | ||
| FAI | 9.9 ± 1.5 | 10.7 ± 2.7 | 8.5 ± 1.7 | 1.8 ± 0.3*† | <0.01 | ||
| Cholesterol (mmol/l) | 5.3 ± 0.3 | 5.1 ± 0.3 | 5.1 ± 0.2 | 4.9 ± 0.2 | 0.81 | ||
| HDL cholesterol (mmol/l) | 1.2 ± 0.1 | 1.1 ± 0.1* | 1.4 ± 0.1 | 1.4 ± 0.1† | 0.01 | ||
| LDL cholesterol (mmol/l) | 3.4 ± 0.3 | 3.2 ± 0.3 | 3.2 ± 0.2 | 2.7 ± 0.2* | 0.15 | ||
| Triglycerides (mmol/l) | 1.6 ± 0.1 | 1.6 ± 0.2 | 1.2 ± 0.1 | 1.7 ± 0.2* | <0.01 | ||
| Fasting glucose (mmol/l) | 4.7 ± 0.2 | 4.6 ± 0.2 | 4.4 ± 0.1 | 4.3 ± 0.1 | 0.74 | ||
| Fasting insulin (mU/l) | 21.5 ± 4.2 | 17.8 ± 5 | 21 ± 4.4 | 20.8 ± 2.9 | 0.1 | ||
| AUC insulin (mU · l−1 · 120 min−1) | 12,333.9 ± 2,046.4 | 8,054.7 ± 1,090.6* | 9,339.8 ± 1,531.5 | 12,413.5 ± 1,616.7*† | <0.01 | ||
| HOMA | 4.7 ± 1.1 | 4.2 ± 1.7 | 4.2 ± 0.9 | 4 ± 0.6 | 0.1 | ||
| RBP4 (μg/l) | 35.9 ± 7.4 | 43.7 ± 6.3 | 35.7 ± 5.3 | 42.6 ± 5.5 | 0.92 | ||
Data are means ± SEM. Baseline data were assessed using one-way ANOVA with intervention as the between-subject factors and intervention data were assessed using repeated-measures ANOVA with time as the within-subject factor and intervention as the between-subject factor.
P < 0.05 for within-group change over study intervention.
P < 0.05 for difference between OCP and metformin group at study beginning or end.